- NewsCategory：
- All Company news Industry news
common105One result
-
0927
NeuCyte Licenses Promising Nov♠"¶≈el Compound for Treatment of Refracto÷≤♥÷ry Epilepsy and Relat≥φ®≤ed Neurological Disorders
NeuCyte, Inc., an innovative bioteβ&$✔ch company focused on developing novel tr'♦eatments for neurological disorders, today anno<unced that it has entered into an exclus→¥ive license agreement with Tr∏®∞illium Therapeutics to advance an ¥★☆undisclosed preclinical compound wit ε✔∏h potential utility in treating refractory epilep↓↑•sy in the form of Dravet syndrome≤α∞ and related disorders.The c¶£↕★ompound covered by this agreement ♣¶₹•has demonstrated highly enc♥♥ouraging activity during studies conducted ≥™α÷by the National Institutα₩♥βe of Neurological Disord¶∏ers and Stroke (NINDS) Epilepsy Therapy Scree≠₩γ∑ning Program (ETSP). It demonstrates ₹±σa superior safety and anti-seizure efficaπ₹cy profile over NINDS benchmark ↓←anti-epileptic drugs (AEDs) in eleven animal modeφπλls. It has also demonstrated broa♠εd efficacy in NIH animal studies for ph♦λ€armaco-resistant epilepsy. As a resul t, this novel agent has gained the prestigious↓±≤ NINDS Red Book status and been selected as a ∑"promising lead drug candidate."This compound is ∞←an exceedingly promisi→★ng antiseizure drug which, although in pλ♥βreclinical development, is quite©↑' efficacious in a wide variety of highly predict₹©σive seizure models," said Roger J. P¥♠orter, MD, Adjunct Professor of Neurology a₹αt the University of Pennsylvania, former× " Deputy Director of NINDS,♠♣ former Chairman of the White §≠↔ House Committee on Brain and Behavioral ₽☆Sciences, and former President of American Epil♥>¶≈epsy Society. "It may prove very ≥€effective for patients $★with epilepsy." As a fi ₽rst-in-class compound with unique mechanism of§&® action profiles, this drug candi↔'≠↑date is likely to have activity across a vari¥×βety of indications. The favorable efficac↕y and safety profile has also been va∑↔↑lidated by NeuCyte's prop✘ ₹"rietary in vitro human iPSC-deri♦>₹φved models."Epilepsy is the fourth most common neβ←π÷urological disease af≠δ↔fecting more than 65 million people of all age₩s worldwide. The comσ ♦plex and multifactorial nature of☆≥& the disorders makes treatment c₽ ♦₹omplicated and challenging. U✔γp to 40% of newly diagnosed epil'π epsy patients are resistant to curr¶±ent therapies which highlig'♦hts the urgent need to develop first-in-cla€¶σss treatments," said Jacqueline→&• A. French, MD, Chief Medical and Innλ→₽ovation Officer of the Epilepsy Fo¥πundation and epileptologist in New York±×<< City. "It is very encouraging to ≠see new developments and therapeutic candidates i↕↓πn this disease area."Under the terms of≠↔ the agreement, Trillium has grant₩₹ed NeuCyte exclusive, worldwide ri₽✘↑ghts to develop and commercialize the c★ ompound. "NeuCyte is committed to bri✘♥nging breakthrough therapies to epilepsy patieλ☆nts and believe that our advantageous translation≤★←al technology platfor♥→m and CNS expertise enable us to optimally adΩ™vance such therapeutic candidates," said Ta≠"♣o Huang, PhD, JD, President and Chief ∏λ≥Executive Officer of NeuCyte. "Tε∞£his licensing agreement allows us to expanε'αδd our pipeline and advance our goal✔≠✘£ of meeting unmet clinical ne<σ★>eds and truly improvinλ₽☆★g patient care and quality of life.¥ "information source:pharma focus AsiaThe≥σ original link:https:https:https:/ λ"'/www.pharmafocusasia.comφ←/news/neucyte-licenses-promising-nove l-compound-for-treatment-of-refractory-β≤$↕epilepsy-and-related-neurological-dis¥✘✔orders2019 Asia-pacific pharma IP Le₽¥φader Summit:http://en.zenseegroup.com/p/510'✘∏↕934/will be held in Bφ✘ββeijing on November 14-15, and wi¥φ✔ll attract more than 500 industry expert¶← s from domestic and fore§✔✘ ign pharmaceutical companies, biote♣☆♦chnology companies, governments, associations&£α, law firms, intellectual property agents and oth♠↔±er companies to attend.Official registration and↑≥≥< consultation channels:Contaγ★↕ct：AnnPhone: 021-65650305☆♣±πEmail：Marketing@zenseegroup.co$ εmhttp://en.zenseegroup.com/p/510934/ -
0926
Ivy Brain Tumor Center and BridgeBio Subs☆¶α★idiary QED Therapeutics Anλ•'≤nounce Collaboration to Advanc¶ ♦e Cancer Research and Trea↔tment Options
The Ivy Brain Tumor Ce¶ nter at Barrow Neurological In• "stitute, today announced a new collaboraπ ¥tion with QED Therapeutics, Inc., &≠a subsidiary of BridgeBio Pδ✘☆÷harma, Inc., (Nasdaq:BBIO) to investigate the FGF'≥R1-3 tyrosine kinase inhibitor, infigratiniφεb, for the treatment of glioblastom≥βφ∑a (GBM). With the goal of addre&σε∞ssing unmet medical needs for those affected by m≤ &σalignant brain cancer, this coll€≈¥↕aboration will focus on ta☆↓rgeting FGFR (fibrobl♥₽ast growth factor receptor) genetic alterati≠↑ons that have been shown to spur growth δ✔©in malignant tumors.“Five to seven perce× γnt of glioblastoma patients’ tσ✔✘×umors are driven by Ω≈✘FGFR signaling,” said Dr. Na€γλ≈der Sanai, director of the Ivy Brain "☆αTumor Center. “We believe our collaboratiδ←on with QED Therapeutics will enable &εus to test how FGFR-driven GBM tumo $rs respond to infigratinib. If prov₩'en effective, we then intend to move forward new >↑λγcombined drug strategies incorp₽§$•orating this target.”In the preclinical studi™σ↑>es, the Ivy Center will employ orthotop✔ically implanted, well-characterφγized FGFR3 fusion patient-deriv≠<ed xenograft models. This ®≈∏is intended to allow the tea"☆×£m to further explore the extent to which the dr≠☆ug crosses the blood-brain barrier and what →♠£↔activity it has in the brain.“We ε©believe the work we are undertaπ"¥•king with the Ivy Center w★γ'ill provide critical insight tΩ☆o shape our clinical development stra δtegy for this disease,“ said Su☆₹<σsan Moran, M.D., M.S.C.E., chief medical of®£ficer of QED Therapeutics. “Our hope is thaσβ≠✘t infigratinib will beco✔®me the backbone of new coε∑ δmbination therapies to treat patient'×s with glioblastoma.”I₹≤₩nfigratinib is an orally admini¥ε stered, FGFR1-3 selective tyrosine ki©<§γnase inhibitor. QED Therapeσ♥δutics has observed activity t©∏hat appears to be meaningful in clinical¥• trials for cancers that are driv↔en by errors in the FGFR genes. €®These include chemotherapy-refra≠→≤ctory cholangiocarcinoma with FGFR2 fu±×≈☆sions and advanced urothelial carc↕δinoma with FGFR3 genet♠βic alterations.“The intricacies ¶≈of the brain have posed significant challenges foγ₽r brain cancer research and the developmen™♣$βt of therapies,” said Gary Li, head φ→∑€of translational medi★γcine at QED Therapeutics. “We believe colla♥'♦borating with the Ivy Brain Tumor C$£←enter will enable us to move swiftly and↓♥ further translational research that we≤ & hope will unlock the doors to effective ∞→treatment options.”information sourceγ★÷:pharma focus AsiaThe original link:https:↕ https://www.pharmafocusasia.com/↓§↔±news/ivy-brain-tumor-centeσ∏αr-and-bridgebio-subsiΩdiary-qed-therapeutics-announce-collaboration-to-σφadvance-cancer-research-an₽ d-treatment-options2019 Asia-pacific phar≤ ma IP Leader Summit:http://en.zenseegr∑δ★≠oup.com/p/510934/will ♦be held in Beijing επ£≈; on November 14-15, and will attract β×"more than 500 industry experts froλΩ&m domestic and forei≠♠gn pharmaceutical companies, biotechnology comp ←anies, governments, associations, σλlaw firms, intellectual property age"←nts and other compan♥'₩σies to attend.Official registration and consulσ≈tation channels:Contact：An∑₩♦♥nPhone: 021-65650305E" εmail：Marketing@zensee↕∑ group.com/forms/view§®/22113/ -
0925
I-Mab Biopharma Announces Clinicaαπεl Collaboration to Evaluate TJC4 in C™ ombination with KEYTRUD☆₩>A® (pembrolizumab)
I-Mab Biopharma ("I-Mab"), γ'®Ωa China and U.S.-based clinical stage biopha≥≈ rmaceutical company exclusively focusing on the™α€ discovery and developm®☆ent of potential first-i✔φn-class and best-in-cl☆☆εass biologics in immuno-oπ&ncology and autoimmune disea'<∞ses, today announced that it has enter¶≤ed into a clinical research col≠'laboration agreement with MSD, aσ♦ tradename of Merck & Co., Inc., Kenilworth♥↕, NJ., USA, to evaluate the combiδnation of I-Mab's TJC4 and →≤MSD's anti-PD-1 therapy, KEYT™→RUDA® (pembrolizumab) in patients with multip 'le cancer types.Under this collaboration agre₩™↑ement, MSD will supp∑←≈ly KEYTRUDA® (pembrolizumab) to I-M♣ ↓ab for use in clinica♠✔εl studies in combination with TJC4, a fully≈∞& human anti-CD47 monoclonal antibody. Both parti¶Ω es will collaborate onγ™±γ a Phase 1 clinical trial, based on an agreed±β and finalized protocol, to evaluate theδ≤ safety, pharmacokinetics, pharmacodynamics™λ÷ and preliminary efficacy of TJC4 and₩£ KEYTRUDA® in patients with m™★ultiple cancer types."TJC4 is a highl"™₩y differentiated anti-CD47 antibody curren₽♣tly under clinical developπ★ment. This collaboration w≤§'ill provide an excellent opportunity t♥δ×o further explore therapeutic potential of coα♦mbining TJC4 with KEYTRUDA® across diffe±"$rent tumor types." said Dr. Jingwu Zang, Foun₩£der and Chairman of I-Mab.KEYTRUDA® i₽≈s a registered trademar¥"♦∞k of Merck Sharp & Dohme Co✘ rp., a subsidiary of Merck & ♠σ Co., Inc., Kenilworth, NJ,α÷ USA.information source:pharma focusε&≠ AsiaThe original link¶§∞ε:https://www.pharmafocusa✔☆sia.com/news/i-mab-bio∑§✘¥pharma-announces-clinical-collaboration-to-e ←valuate-tjc4-in-combination-with-keytruda201± §>9 Asia-pacific pharma IP Leader Summi ₹£∑t:http://en.zenseegro≠×≈up.com/p/510934/ will be held in ÷₩";Beijing on November 14-15, and×♦ will attract more than 500 industry☆★ experts from domestic and foreign ph↕•≈armaceutical companies, biotechnology companies,≤• ✘ governments, associations, law fi≤β'rms, intellectual property agents and otΩ'∏her companies to attend.Official registra₩φ≥tion and consultation c>>₹hannels:Contact：AnnPhone: 021-6565♦↑0305Email：Marketing@zenseegroup.comhttp://ww♠≥w.zenseegroup.com/forms/view/22113/ -
0923
Boehringer Ingelheim∑¥∑ Partners with Inflammasome Therapeutics ✘™'σto Develop Novel Therapies for Patient"€♥s with Retinal Diseases
Boehringer Ingelheim and Inf™Ω∏lammasome Therapeuti≥© cs Inc. (Inflammasome) today a$€±nnounced they have entered into ✔a co-development and lice♥™¶nse agreement to develop up↓≤ to three therapies for ≥♥♥patients with retinal diseases. By combi↕•¶ning Inflammasome’s unique intravitreal (IVT) d☆>↑rug delivery technologies with Boehringe↑ε≈r Ingelheim’s compounds fγ₽>rom its retinal disease pipeline portfolio,$¥ Boehringer Ingelheim aims to develop novel ther£¥★apies for retinal diseases.In 2β₹≤019 there were an estimated 82 millionδ•♠ patients in the seven key countries (U.S≈¥., Japan, Germany, U.K., Spain, I→׶taly, France) affected by oneΩ®♠• of the three major forms of re€ tinal disease: Age related macular d <↓egeneration (AMD), diab§™¶→etic retinopathy (DR), and diabet∑÷ic macular edema (DME). Globaπ♥★lly, the prevalence rates of ★•∑↕these and other retinal diseases are ex×€ pected to increase over the next 10 years >←₹primarily due to aging populations φ and the global diabetes epidemic. D≈∞espite therapeutic advances in some disease ar↓←eas during the past years, the real wor¶±✘ld results are poor, and there are no<×♥ or only limited treatment options↕λ in many areas, resulting in an overall high unm<™♣©et need. The collaboration between Boehringe♥γr Ingelheim and Inflammasome ai≈←↑↕ms to address this chall♣φ↕enge by using Inflammasome’s technolog♥¶>y to deliver therapeutics in a biodegradaεΩδble gel formulation into α£↕Ωthe eye.“We are delighted to ent∑λ€er into a collaboration with a company>"' of Boehringer Ingelhεσ®eim’s stature,” said Paul Ashto®$>n, Chief Executive Officer of Inflammasome Thera£€∞®peutics. “We look forward to working with their t&λeam to leverage our respectσγ<₩ive technologies and ♦¶♠expertise to develop ne↔©♦<w therapies for devastating retinal dis♥←>₽eases leading to blindness. This collaborati± ÷on fits our strategy of advancing the compa±σ"ny via both collaborations a÷♠©©nd internal development.”“Boehringer Ingelheim iδ€®®s looking forward to developing Inflammasome’↕ ∞'s novel technology for the del< ivery of our first-in- class retina←l disease compounds workin∏≠βg jointly with Inflamma↔✔some’s highly experienced scientific t♠∑eam,” said Clive R. Wood, PhD, Senior Corporaφβte Vice President, Discovery ←÷≈ Research at Boehringer Ing©₽<elheim. “This will ena♠☆πble us to develop a broad range of •φ₩ novel therapy options for the many patients withσ←≈ retinal diseases waitin∑φ¥≠g urgently for better and ↕™new therapy options.”Boehringer Ingelheim¥>→ takes a holistic approach in the develop∏ment of novel retinal disease therapies,™" targeting key mechani↔✔★αsms in the pathogenesis of retinal diseases.↕→ The company has built a comprehensive pi$φpeline portfolio of next ®β←™generation therapy approaches φσin various stages of development up to Phasδβ∞e 2 in macular degeneration, diabetic retinal d&β≠iseases and beyond. Inflammasome’s novel deli→$→✔very technology using a long-acting degradable Iγ↑VT implant complements this portfolio.InflΩΩammasome is entitled to receive up to $160 mi♣≤llion in up-front, r>§Ω'esearch and development >×™support and milestone gated development ←£payments as well as tiered roy≈₽alties based on future commercial sales of develo₩<ped products and other "÷milestones due on commercializati✔₹♣Ωon.information source:pharma focus AsiaThe o×αriginal link:https://www.pharmafocusasia.com¶ σ/news/boehringer-ingelheim-partners>±↕-with-inflammasome-therapeutics-toλ↔∞-develop-novel-therapies-for-patient<>↔s-with-retinal-disea♥§∑γses2019 Asia-pacific pharma IP Leader Summ$←☆it: http://en.zenseegroup.com/p/510934/♣ will be held in Beijing on✘™" November 14-15, and will attract more thε♠₩an 500 industry expert₩$ αs from domestic and foreign phar¶≤≈maceutical companies, biote♠¶πchnology companies, gov∏✔ernments, associations, law firms, inλ¥₽tellectual property agents and other companiesε₽✘< to attend.Official registration and consu<¥¶ltation channels:Conta≠♥"×ct：AnnPhone: 021-65650305Email：Marketing@zβ♠♣enseegroup.com/fo≠↕rms/view/22113/ -
0920
Clene Nanomedicine, ≥✔Inc. Announces Selection of ↕₩®CNM-Au8 for the Harvard Led HEALEY AL♣÷S Platform Trial, a Clin↑> ©ical Trial for Amyotrophic Lateral Sclerosis
Clene Nanomedicine, Inc., a clinica∞l-stage biopharmaceutical company, ann♠ ↕ounced today that the Sean M. Healey & AMG ↔ Center for ALS at Mass General has selected CNM- ↑Au8 for inclusion in the f♣↔irst ever Platform Trial for tεhe treatment of amyotrophic lateraσ×±≠l sclerosis (ALS).The Heale&δ∞y Center issued a call earlσ∏ier this year for the best therape•₹∞δutic candidates to apply for entryβ& into the HEALEY ALS Platform Trial. They rec™∏Ωeived responses from nearly 30 applicants acros♦Ω♥s ten countries. Member ≈γs from the Healey Center Science♠ ↕ Advisory Committee, a group ofε£σ♠ renowned ALS scientists,γ&♦↔ chose the top five the∏✘™rapeutic candidates, φ¶including Clene's lead clinΩ÷'ical asset, CNM-Au8. The selection↑§ ∞ of CNM-Au8 into the Healey ALS Platform Trial→★ includes substantial financial support and δ★δ→provides access to over 50 ♥×λexpert ALS clinical trial sites across the Unit≤λ₽ed States."Our goal," said Merit Cu∞☆dkowicz, MD, MSc, Director of the Healey Center÷≠™∏, "is to lower the barriers for our pharma aλ'σnd academic colleagues to bring their ex£citing therapies for ALS fo≥♦rward to clinical trials. We are det&λ↕εermined to accelerate therapy development f↕ε≠≤or ALS."Important preclinical work ★Ω&supporting the effort with CNM-Au≠↔8 was performed in th↔ ♥e laboratory of Nicholas J★ ≤€. Maragakis, Director of the ALS Center for Cell &>Therapy and Regeneration Research at Johns Hopkεα¥γins, using human induce∑$€d pluripotent stem cellsσσ from ALS patients. D≠€r. Maragakis is Chair of Clenβ∞♦e's Scientific Advisory Board for ALS.Dr. Jonath ¶≤an Glass, Professor of Neurolog✔♠"y and Pathology at Emory University Sch§♠☆ool of Medicine, as well as Director of the E↓↓★mory ALS Center, remarked, "CNM-Au8 is ♠↕≈quite an interesting compound that is ready for ≤α∑£testing in ALS clinic£λal trials. Its inclusion in the P§>♠latform Trial initiative is an excellent way to m∏ ove forward for the deve★₹lopment of CNM-Au8 as a potential th♣☆'erapeutic for ALS.""We are very pleased∞≤∞ Clene's CNM-Au8 has been selected for ∏σ¶participation in the Healey ALS→₽λ¶ Platform Trial. We believe →βthe unique mechanism of CNM-Au8 represents a prσβ≥omising new approach for t₽♣he treatment of neurodegen±♥≈erative diseases, in§✘cluding ALS, with the potential fo£§™r meaningful impact for th∞Ω™e community of people diag"γnosed with this devastating aγ♥γnd debilitating disease," said Rob Ethering±∞ton, President and CEO of♠δ ↑ Clene. "We are continuing the development of C♠™≥γNM-Au8 in several clinicε ←al studies set to launch ₹★•↔later this year."2019 Asi™→ε<a-pacific pharma IP Leader Summit:Ω"★ http://en.zenseegroup.co ÷m/p/510934/will be held in&n♠¥¶bsp;Beijing on Nove¶&♣δmber 14-15, and will att>>↑ract more than 500 industry experts from domesticδ✔ and foreign pharmaceut§γical companies, biotechnology com↔↔¶panies, governments, associations, §★law firms, intellectua∑✘≈l property agents and other companies t♣←σo attend.Official registrationσ& and consultation cha∏¶✔nnels:Contact：AnnPhone: 021-65650305Email：Mφ£φarketing@zenseegroup.comhttp:φ×α♦/forms/view/22113/
Contact Us
Zensee_Daystar online
© 2011-2016